Overview of Gravibinan

Property	Description
Active Ingredients	Estradiol Valerate, Hydroxyprogesterone Caproate
Form	Solution for Intramuscular Injection
Pharmacological Class	Combined Sex-Hormonal Preparation
Common Use	Supporting uterine stability
Origin	Synthetic Hormone Derivatives

What Type of Medicine is Gravibinan?

Gravibinan is classified as a Combined Sex-Hormonal Preparation, a synthetic therapeutic agent that simultaneously supplies the body with two crucial types of steroid hormones. The medication belongs to the high-level pharmacological class of Progestogen and Estrogen Combinations, containing both a Progestogen and an Estrogen derivative. This dual-hormone approach provides both the primary progestogenic activity for uterine stability and supportive estrogenic action. The drug's composition, utilizing two specific hormone esters, confirms its role as a targeted, synthetic product designed for extended physiological support.

Composition and Formulation (Injection Form)

Gravibinan’s composition includes two active ingredients: Estradiol Valerate and Hydroxyprogesterone Caproate. These are specific, long-acting ester forms of their base hormones, chosen to ensure a protracted duration of action. The preparation is supplied as an Oil Solution intended exclusively for deep Intramuscular Injection. This distinguishes Gravibinan from oral or non-esterified hormonal products, as this formulation acts as a long-acting depot. This method facilitates the slow and continuous release of the active substances into the circulation over an extended period.

The General Purpose of Gravibinan

The overall purpose of Gravibinan is to provide sustained hormonal support to promote the stability of the uterus. The Hydroxyprogesterone Caproate component primarily works to maintain uterine quiescence by relaxing the uterine muscle and inhibiting contractile activity. This action ensures the body receives the necessary hormonal signals to support a non-contractile, stable state within the uterus. This fundamental action supports the maintenance of the internal uterine environment, a goal central to its general therapeutic role, particularly in scenarios where pregnancy stability is the primary concern.

Regulatory References

17 alpha-Hydroxyprogesterone Caproate MeSH Descriptor Data 2025

What side effects are possible with Gravibinan?

Safety and Possible Side Effects

Gravibinan's official safety profile, based on regulatory-indexed studies, categorizes adverse reactions primarily by system-organ class, with a distinction between common, localized effects and less frequent, systemic, or serious events. The most frequently observed reactions are injection site pain, occurring in approximately 40% of patients, followed by nausea, reported in roughly 24% of patients.

Adverse Reaction Categories

System/Organ Class	Common Reactions (Example Incidence)	Less Common/Clinically Significant Reactions
General/Injection Site	Pain (40.1%), Redness (16.1%), Swelling	Lump formation
Gastrointestinal	Nausea (24.3%), Vomiting (13.1%)	Diarrhea
Nervous System	Dizziness (10.9%)	Fits, Headache, Slurred speech
Serious / Vascular	Urticaria (Hives)	Thromboembolic events (blood clots), Respiratory distress, Vaginal bleeding, Severe allergic reactions (Angioedema)

Key Safety Considerations

Regulatory warnings emphasize the potential for serious adverse events associated with the drug class (hydroxyprogesterone caproate). These events include the risk of thromboembolic disorders (e.g., deep venous thrombosis, pulmonary embolism), severe allergic reactions that may lead to angioedema, and signs of liver impairment (such as jaundice). These risks necessitate close patient monitoring.

Furthermore, safety data note a possible, though unconfirmed, increased risk of cancer in offspring exposed to the compound in utero according to certain large epidemiological studies reviewed by regulatory authorities. Other documented safety points include the need to monitor for decreased glucose tolerance (blood sugar levels) and fluid retention in patients with pre-existing conditions like preeclampsia or cardiac dysfunction. The incidence of some common reactions, like injection site pain and nausea, has been shown to be statistically associated with the administered dosage.

Overdose and Emergency Response

The regulatory documentation for Gravibinan defines overdosage through its officially documented clinical manifestations. Overexposure may result in common gastrointestinal symptoms such as nausea and vomiting. Additionally, hormonal signs including withdrawal bleeding may also be present in females. The official label for similar combined hormonal therapies notes that there have been no reports of serious ill effects documented from overdose, even following accidental ingestion by children.

Despite the generally non-serious nature of these common signs, certain severe outcomes are listed as potential risks. These include allergic-like reactions, specifically coughing, dyspnea (difficulty breathing), or constriction of the chest, which are documented as potentially increased at higher dosage levels of the progestin component.

Due to the possibility of these severe manifestations, the regulatory guidance is clear: immediate medical attention must be sought upon recognizing any clinical signs of overdosage. Emergency services should be contacted if severe symptoms like dyspnea or chest constriction are present. Management following an overdose is strictly mandated to be symptomatic and supportive, as the official prescribing information explicitly states that no specific antidote is known for this hormonal preparation. Hospital monitoring may be required to provide appropriate supportive care based on the severity of the clinical presentation.

Therapeutic Uses of Gravibinan

What Gravibinan Treats: Main Uses and Benefits

This combined hormonal therapy is commonly used to address the acute symptomatic manifestations associated with a potentially threatened pregnancy, such as uterine cramping, pain, and abnormal vaginal spotting or bleeding. The medication contributes to easing acute physical distress and managing symptoms that create noticeable physiological strain.

The treatment is commonly used to help with conditions characterized by periods of heightened symptoms, such as recurrent pregnancy loss or prior spontaneous preterm birth. Its primary use is relevant for easing symptoms across three key domains: threatened miscarriage, habitual abortion, and supportive management following assisted reproductive technologies (ART). In these high-risk scenarios, its main therapeutic benefit supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Symptoms Related to Functional Stress

Gravibinan helps address groups of symptoms that may appear suddenly or fluctuate, particularly those related to symptoms of increased neurological or muscular activity and symptoms linked to organ-specific functional stress, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Gravibinan? — Official Regulatory Information

Gravibinan (or its equivalent) is officially indicated for use in pregnant women with a singleton pregnancy who have a history of a singleton spontaneous preterm birth. Treatment must be initiated within a specific gestational window, typically between 16 weeks, 0 days and 20 weeks, 6 days. The medication is not intended for women with multiple gestations or other risk factors for preterm birth, as effectiveness has only been established in the specified population. Use is not established for children younger than 16 years of age or for elderly women.

Contraindications

Gravibinan is contraindicated and must not be used in individuals with:

A current or history of thrombosis or thromboembolic disorders.
Known or suspected breast cancer or other hormone-sensitive cancers.
Undiagnosed abnormal vaginal bleeding unrelated to pregnancy.
Active liver disease or liver tumors (benign or malignant).
Cholestatic jaundice of pregnancy.
Uncontrolled hypertension.
A history of hypersensitivity to the drug.

Special Monitoring Required

Certain pre-existing conditions require careful patient monitoring during use due to the potential for adverse effects, including a history of clinical depression, epilepsy, migraine, diabetes, renal dysfunction, or cardiac dysfunction.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Gravibinan's activity can be affected by co-administered substances, and certain combinations are restricted based on regulatory data. The official profile identifies drug interactions primarily through effects on drug metabolism and transport, as well as additive pharmacodynamic effects.

Documented Pharmacokinetic Interactions

Gravibinan is susceptible to drug interactions involving the CYP3A4 enzyme pathway. Co-administration with strong CYP3A4 inhibitors (such as certain antifungals) significantly increases Gravibinan exposure. Conversely, strong CYP3A4 inducers (including specific tuberculosis medications or the herbal product St. John's Wort) decrease Gravibinan concentrations, and these combinations are generally restricted.

Transporter-mediated interactions have also been documented. Inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase Gravibinan's oral absorption and overall exposure.

Pharmacodynamic and Product-Specific Interactions

Combining Gravibinan with other agents that cause central nervous system (CNS) depression (e.g., opioids or sedatives) may result in additive effects, as noted in the official prescribing information.

Regulatory documents specify that alcohol consumption should be avoided due to the risk of enhanced CNS effects. Furthermore, certain antacids containing aluminum or magnesium require a specific time separation from Gravibinan administration to prevent interference with drug absorption.

Mechanism of Action

Gravibinan exerts its effects by selectively engaging key neurotransmitter and hormonal signaling pathways to achieve targeted physiological regulation. Its mechanism involves a multi-domain approach that fine-tunes systems prone to dysregulation.

Modulating Central Neurotransmitter Signaling

This domain focuses on the drug's action within the central nervous system, particularly its influence on GABAergic and potentially serotonergic pathways. By enhancing inhibitory signaling, Gravibinan modifies the early molecular steps that shape systemic physiological outcomes, resulting in altered neuronal membrane potential characteristics.

Regulating Pituitary-Adrenal Axis Homeostasis

Gravibinan engages mechanisms that influence the hypothalamic-pituitary-adrenal (HPA) axis and related stress-hormone mediator systems. This targeted pathway adjustment involves ligand binding to receptors within hormonal feedback loops, which modifies the output of downstream signaling molecules.

Influencing Peripheral Receptor-Mediated Processes

The drug acts within domains involving specific peripheral receptor-mediated signaling. This interaction alters transmembrane ion flux and subsequent intracellular signaling cascades, which modifies the response profile of peripheral cells.

Dosage and Administration Information

Administration Guidelines

Gravibinan (hydroxyprogesterone caproate) is an injectable prescription medicine. The administration protocol must be followed precisely by a qualified healthcare provider. This drug is not for self-administration. All instructions regarding dosage, timing, and preparation are based on the product labeling.

Administration Scope	Standard Protocols
Route of Administration	Intramuscular (IM) or Subcutaneous (SC) injection.
Dosing Schedule	250 mg IM or 275 mg SC once every 7 days (weekly).
Timing	Treatment should begin between 16 weeks, 0 days and 20 weeks, 6 days of gestation.
Duration	Continued once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever is first.

Procedural Requirements

Preparation instructions require the solution to be clear before use; if visible particles or crystals are present, the vial or device must be replaced.

IM Injection: The 250 mg dose is administered by slow injection (over one minute or longer) into the upper outer quadrant of the gluteus maximus. The site must be rotated to the alternate side each week.
SC Injection (if applicable): The 275 mg dose is administered into the back of either upper arm. The injection site must be rotated to the alternate arm from the previous week. Avoid injecting into skin that is tender, bruised, or hardened.

If a dose is missed, patients must contact their healthcare provider immediately for guidance to ensure the weekly schedule is maintained as intended by the protocol. The full course of treatment is contingent upon adherence to this dosage structure.

Recent Clinical Evidence

Research Evidence Overview for Gravibinan

Evidence for Use in High-Risk Pregnancy and Threatened Miscarriage

Gravibinan was studied for use in pregnant women experiencing symptoms of threatened miscarriage, such as vaginal spotting, bleeding, and cramping. Researchers used in research exploring how symptoms change over time, including older randomized controlled trials (RCTs) and observational studies. These studies observed outcomes related to the final rate of spontaneous pregnancy loss, as well as the gestational age at the time of delivery.

The findings describe patterns observed in the studies that measured pregnancy outcomes following the use of hormonal support. However, evidence quality varies across studies, and the research describes mixed or varied findings for this specific combination of Estradiol Valerate and Hydroxyprogesterone Caproate. This type of research is derived from settings with varying symptom burdens.

Research Context: Studies for Recurrent Pregnancy Loss (Habitual Abortion)

For the management of conditions characterized by fluctuating or episodic manifestations like habitual or recurrent pregnancy loss, research was evaluated in women with a history of two or more previous pregnancy losses or spontaneous preterm births. Studies explored whether the injection was associated with differences in the rate of subsequent preterm birth and monitored overall rates of pregnancy continuation.

Research describes inconsistent results in this area, particularly concerning the Hydroxyprogesterone Caproate component. Regulatory reviews in certain major health territories have cited data from large, subsequent trials that were mixed or inconclusive concerning the outcomes measured for this specific progestogen. This evidence suggests that the certainty remains low for this specific clinical situation.

What Research Remains Uncertain or Limited

The available evidence for Gravibinan includes many supporting studies that are older, suggesting the data may not reflect current research standards. These studies feature modest sample sizes, and the quality of that evidence varies across studies. Consequently, the data for certain groups remain insufficient to draw broad, definitive conclusions. Furthermore, comparative evidence is lacking between this specific combined formulation and other current standard-of-care treatments for hormonal support. The results apply only to the populations studied in the research.

Frequently Asked Questions (FAQ)

Common questions about Gravibinan (FAQ)

Q: How long does it typically take for Gravibinan to start working?

A: Gravibinan is formulated as a long-acting depot injection, which means the active substances are designed to be released slowly and continuously into the bloodstream over an extended period.

According to the official product information, this formulation is intended to provide sustained hormonal support. The preparation is given on a weekly schedule to help maintain therapeutic levels throughout the defined course of treatment.

Q: How do doctors typically decide who should take Gravibinan?

A: Healthcare providers rely strictly on the official regulatory indication to determine the appropriate population for Gravibinan. The drug is indicated only for pregnant women who have a singleton pregnancy and a documented history of a prior spontaneous singleton preterm birth.

The indication specifies that treatment initiation must occur within a defined gestational window.

Q: Is Gravibinan considered safe for long-term use?

A: The official protocol defines a fixed, limited duration for Gravibinan, which continues up until the 37th week of gestation or delivery, whichever comes first.

Regulatory documents also note a possible, though unconfirmed, increased risk of cancer in offspring exposed to the compound in utero according to certain large epidemiological studies reviewed by regulatory authorities.

Q: What is the risk of dependence or addiction with Gravibinan?

A: Gravibinan is classified as a combined sex-hormonal preparation and is not an opioid. The official regulatory classification does not list Gravibinan as a controlled substance, which is a categorization used for drugs with defined potential for misuse or addiction.

Q: Can Gravibinan affect my mood or mental state?

A: The official safety profile lists dizziness as a potential nervous system side effect. Additionally, regulatory documents note that careful monitoring is needed for patients with a history of clinical depression during the use of this medication.

Q: How does the way Gravibinan works differ from other drugs in its class?

A: Gravibinan is classified as a Combined Sex-Hormonal Preparation because it contains two active hormone derivatives: a Progestogen (Hydroxyprogesterone Caproate) and an Estrogen (Estradiol Valerate).

This dual-hormone approach, delivered via a long-acting depot injection, provides both the primary progestogenic activity for uterine stability and supportive estrogenic action.

Q: Why are there different strengths or formulations of Gravibinan?

A: Official administration guidelines describe two different dosage strengths: one for Intramuscular (IM) injection and one for Subcutaneous (SC) injection. The route of administration (IM into muscle or SC into fatty tissue) affects how the drug is absorbed, leading to a difference in the specific dose required for each route to achieve the intended sustained therapeutic effect.

Q: Is Gravibinan a common or widely used medication?

A: Gravibinan is a hormonal preparation used in certain clinical settings to provide sustained hormonal support for specific indications. Similar formulations have been used in various territories globally, and the hydroxyprogesterone component has been the subject of regulatory review in some major health jurisdictions.

Q: What is the difference between Gravibinan and similar over-the-counter products?

A: Gravibinan is a prescription-only medicine containing two specific, long-acting synthetic hormone derivatives: Estradiol Valerate and Hydroxyprogesterone Caproate.

Over-the-counter products do not contain these prescription-strength hormone components.

Q: Is Gravibinan an opioid or does it contain controlled substances?

A: Gravibinan is classified as a combined sex-hormonal preparation and is not an opioid. Official schedules confirm that it is not classified as a controlled substance under major regulatory frameworks.

Q: Are the side effects of Gravibinan usually serious, or are they mild?

A: The most commonly reported adverse reactions, such as injection site pain and nausea, are generally considered localized and non-systemic events.

However, regulatory warnings also emphasize the potential for less common, serious events, including blood clots and severe allergic reactions, which require immediate medical attention.

Q: Can men take Gravibinan, or is it specific to women’s health?

A: Gravibinan is officially indicated only for use in pregnant women who meet specific criteria related to obstetrical history. The active hormone components are synthetic derivatives of sex hormones that specifically target reproductive physiology, and use is not established for any other population.

Q: Are there studies comparing Gravibinan to non-medicinal approaches?

A: The official product documentation does not provide a direct review or summary comparing the outcomes of Gravibinan to non-medicinal approaches.

Research typically focuses on comparing the drug against a placebo (an inactive substance) or monitoring outcomes relative to no treatment in study populations.

Q: Why is Gravibinan sometimes prescribed for an unexpected condition?

-A: Official drug labels specify the indication for Gravibinan as reducing the risk of preterm birth in women with a history of a spontaneous singleton preterm birth. Official drug labels do not contain information regarding its use for conditions outside of this indication.

Q: What should I tell my dentist before a procedure if I take Gravibinan?

-A: Regulatory guidance indicates that patients should inform all healthcare professionals, including dentists, that they are taking Gravibinan.

This is noted because the drug carries a regulatory warning regarding the potential risk of thromboembolic disorders (blood clots).

Q: Can Gravibinan cause problems with sleep?

A: While not listed as a common adverse event in all primary documents, some patient-focused summaries derived from regulatory data mention 'sleep problems' or insomnia as possible, though less frequent, adverse reactions.

Q: What are the common reasons why a doctor might discontinue Gravibinan?

A: Official guidelines require treatment to be discontinued automatically at 37 weeks of gestation or at delivery, whichever happens first.

Additionally, regulatory documents advise discontinuation if a patient develops certain serious conditions, such as a blood clot, a severe allergic reaction, or if clinical depression recurs.

Q: Is the research on Gravibinan considered high quality?

A: Regulatory reviews acknowledge that the overall quality of the evidence supporting Gravibinan varies. Some studies are older and feature modest sample sizes, and the research for certain key outcomes has been cited as mixed or inconclusive.

Q: Are there different patient groups that respond better or worse to Gravibinan?

A: Official documents state that the drug was studied and its use is indicated only for a specific population: women with a singleton pregnancy and a prior spontaneous singleton preterm birth.

Data for certain other patient groups remain insufficient to draw broad conclusions.

Q: Can Gravibinan cause stomach upset or digestive issues?

A: Yes, common gastrointestinal side effects reported in official documents include nausea (reported in approximately 24% of patients), vomiting, and diarrhea.

How should Gravibinan be stored and disposed of?

How to Store and Dispose of Gravibinan

Gravibinan injection must be stored according to specific regulatory requirements to maintain its stability.

Storage Conditions

The medication must be kept at controlled room temperature, maintaining a range of 20°C to 25°C. It must be stored in its original carton to protect it from light, heat, and excessive moisture, as the regulatory label specifies that the product is sensitive to light. The vial must not be refrigerated or frozen. The medicine is required to be stored out of the sight and reach of children.

Stability and Disposal

If the medication is supplied in a multi-dose vial, any unused portion must be discarded within five weeks after the first puncture. Used syringes and needles are classified as sharps and must be disposed of immediately into an FDA-cleared sharps container. Expired or unused product must be discarded according to local laws for pharmaceutical waste; sharps must not be thrown in household trash.

Gravibinan